Clinical trial · Interventional
A Modular Cloud Platform For Fertility Preservation
A Modular CLoud Based Platform To Enhance Fertility Preservation Awareness: Design, Pilot Testing And Randomized Controlled Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The research was designed as a randomized controlled study to determine the effectiveness of a modular cloud-based training platform in increasing awareness of fertility preservation. The study aims to develop a free, modular, cloud-based, sustainable digital platform to increase fertility awareness. The platform will provide basic information on fertility preservation methods in plain language to support informed decisions. Content will be based on European Society of Human Reproduction and Embryology (ESHRE) , International Federation of Gynaecology and Obstetrics (FIGO) and Asian Society of Gynecologic Oncology (ASCO) guidelines. The study targets not only cancer patients but also women requesting fertility preservation for medical or social reasons. In the first stage, the platform will be designed with the ADDIE instructional design model (Analysis, Design, Development, Implementation, Evaluation) and content created per international guidelines. In the second stage, the prototype will be pilot-tested and revised. In the third stage, effectiveness will be tested through a randomized controlled trial. Educational modules will be provided to the intervention group, while the control group will receive brochures. The study will include women aged 18-45 with early-stage gynecological cancer (cervix, ovary, tube, endometrium) at Prof. Dr. Cemil Tascioglu City Hospital, untreated. Participants must have Turkish literacy and internet access. Sample size, calculated with G\*Power, is 140 total (70 per group).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Fertility Preservation | — | UNRESOLVED | — |
| Gynecologic Cancers | Malignant Female Reproductive System Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Developing a Modular Cloud-Based Platform to guide decision-making in fertility preservation | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- Control- Routine information
- description
- The control group will be given an educational brochure with similar features for fertility preservation.
- type
- EXPERIMENTAL
- label
- İntervention- Using the educational platform
- description
- Prof. Dr. Cemil Taşçıoğlu City Hospital will divide female patients of reproductive age (18-45 years) who have been diagnosed with gynecological cancer (early-stage cervical, ovarian, tubal, and endometrial cancer) and have not yet started treatment, and who have been referred for egg/ovarian tissue/embryo freezing, into two groups. The intervention group will use the cloud-based sustainable education platform developed for fertility preservation within the scope of the study. The control group will be given an educational brochure with similar features for fertility preservation.
- interventionNames
- Other: Developing a Modular Cloud-Based Platform to guide decision-making in fertility preservation
Primary outcomes (4)
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * Women of reproductive age between the ages of 18 and 45, * Diagnosed with early stage cervical cancer, ovarian cancer, tubal cancer and endometrial cancer and whose treatment has not started, * Those who have a smartphone and can use the platform, * Volunteering and giving informed consent, * Turkish literate, * Individuals who do not report mental problems * Do not have children, * Marital status is married or single. Exclusion Criteria: * Neurological disease (e.g., stroke, multiple sclerosis) or cognitive impairment, * Advanced-stage gynecologic cancers, * Failure to complete the follow-up period, * Initiation of oncologic treatment during the study period, * Non-completion or incomplete completion of the data collection instruments, * Non-use of the platform among participants allocated to the intervention group, * History of prior cancer treatment.
References
Publications (0)
Data not yet available